Company profile: Akebia Therapeutics
1.1 - Company Overview
Company description
- Provider of treatments for ischemia and vascular diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Akebia Therapeutics
Embark Biotech
HQ: Denmark
Website
- Description: Provider of biotech research identifying novel cell surface receptors that physiologically regulate fat tissue calorie-burning and glucose and lipid uptake; founded in 2017 and headquartered in Copenhagen, Denmark.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Embark Biotech company profile →
MetaVia Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage multimodal disease-modifying therapies, including DA-1241, an oral GPR119 agonist in Phase 2a for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and DA-1726, a once-weekly dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity, with a Phase 1 clinical trial expected to begin in 2024.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetaVia Therapeutics company profile →
OrsoBio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for severe metabolic disorders, including TLC-3595 (selective ACC2 inhibitor) to improve insulin sensitivity in type 2 diabetes; TLC-2716 (liver-targeted LXR inverse agonist) to lower plasma triglycerides and cholesterol in severe dyslipidemias; mitochondrial protonophores (TLC-6740, TLC-1235) to increase energy expenditure; and an ACMSD inhibitor to augment NAD+ and mitochondrial function in liver/kidney dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrsoBio company profile →
Theratechnologies
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies, including Trogarzo for HIV in individuals with limited treatment options due to resistance, intolerance, or safety considerations; EGRIFTA SV (tesamorelin) to reduce excess abdominal fat in HIV patients with lipodystrophy; and Long Acting Peptides and the SORT1+ oncology platform. Pipeline includes tesamorelin for NASH, F8 bioequivalent formulation, and a multi-dose pen injector in development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theratechnologies company profile →
Jecure Therapeutics
HQ: United States
Website
- Description: Provider of research and development focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jecure Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Akebia Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Akebia Therapeutics
2.2 - Growth funds investing in similar companies to Akebia Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Akebia Therapeutics
4.2 - Public trading comparable groups for Akebia Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →